Pulsatile release histamine H2 antagonist dosage form
US6663888B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 25, 2002 |
| Grant date | Dec 16, 2003 |
| Priority date | — |
| Expiry date | Jan 25, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/5047
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A unit dosage form, such as a capsule or the like, for delivering drugs into the body in a circadian release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need at different times during the dosing period, i.e., mimicking the circadian rhythm and severity/manifestation of gastric acid secretion (and/or midnight gerd), predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.